Healthcare and life sciences

VISCHER

Divided between Zurich and Basel and described by clients as having the ‘best reputation for driving biotech deals in Switzerland’, VISCHER’s broad offering spans the full range of corporate issues within the life sciences space, in addition to acting in administrative disputes concerning reimbursement and distribution issues. Stefan Kohler leads the team alongside the ‘outstanding’ Matthias Staehelin. Kohler is a key name for licensing and R&D agreements, in addition to handling both administrative and patent disputes. Staehelin is recommended for his deep knowledge of series financing and fundraising issues, often advising investors and major biotech companies and investors. Christian Wyss is particularly adept at advising on licence terms, and remains a key contact for start-ups, while Vincent Reardon utilises his broad corporate expertise to assist with M&As and IPOs.

Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

‘Best reputation for driving biotech deals in Switzerland. A deep roster of excellent people with technical expertise and a proven track record allows one to find a partner who is a good personal match.’
‘Very strong experience in the biotech industry and an excellent network within it. For years I have been working with Vischer and always have received an excellent service. It always is of the highest quality, with strong long-term thinking and down-to-earth advice. They are proactive and notice if things could go wrong. They give a balanced review of risks and opportunities and also give their judgement.’
‘High-quality and pragmatic advice on highly complex matters. The practice can be fully trusted, and they want the best for the client.’
‘Matthias Staehelin is an outstanding partner and Vincent Reardon a great associate.’
‘Great knowledge, very speedy, very collaborative.’
‘Stefan Kohler - huge ownership of matters, knowledge, great communicator.’

Key clients

LASCCO SA
EraCal Therapeutics
Memo Therapeutics
T3 Pharmaceuticals
Proteomedix
Lallemand
Epiterna
LimmaTech Biologics
Redbiotec
Mosanna Therapeutics
Forty51 Ventures
Norgine Ventures
Versantis
Oculis
Anokion
Resistell
AMR Action Fund
GlycoEra AG
Medartis
ATANIS Biotech
Novo Nordisk
Thermo Fisher Scientific
Bausch Health
ten23 Health AG
Bachem Holding AG
Delica
Anjarium Biosciences AG
Spexis
Combioxin SA
evitria Group
ImmunOs Therapeutics AG
Anaveon AG
Cimeio Therapeutics
MiniNaviDent AG
T3 Pharmaceuticals
ClearView Healthcare Partners
RELIEF THERAPEUTICS HOLDING SA
Cytokinetics (Switzerland) GmbH

Work highlights

Advised the shareholders of T3 Pharmaceuticals AG, a company developing genetically engineered bacteria targeting solid tumours, in selling the company to Boehringer Ingelheim for up to CHF450m.
Represented Novo Nordisk in an appeal to the Federal Administrative Court against the pricing of a high-turnover drug.
Advised listed Bachem Holding AG, a company specialising in the development and production of peptides and oligonucleotides, in raising CHF 108.1m through an accelerated bookbuilding process.